Clinical outcome of a patient cohort with acute hepatitis B

Souza, Laura Alves de; Mattos, Ângelo Alves de; Fiorini, Maristela; Ribeiro, Polyanna; Tovo, Cristiane Valle

doi:10.6061/clinics/2013(05)21

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The very high rate of chronic infections (91.2%) in this study compared with 14.1% reported by de Souza et al [29] in Brazil could be attributed to highly endemic circulation of HBV in the sub-Saharan region as compared to Brazil, a region reported to have HBV low endemicity. This may further accounts for the higher cases of liver cancers reported in sub-Saharan Africa [3].…”

Section: E M Mbaawuaga Et Alcontrasting

confidence: 45%

See 1 more Smart Citation

Hepatitis B Virus (HBV) Serological Patterns in Benue State, Nigeria

Mbaawuaga¹,

Iroegbu²,

Ike³

2014

OJMM

View full text Add to dashboard Cite

A total of 1535 randomly collected blood specimens from different groups of consenting subjects in Benue State, were screened by ELISA for Hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis Be antigen (HBeAg) and Hepatitis B core IgM antibodies (HBcIgM). The pattern of occurrence of these HBV markers in each blood sample was used to determine individuals with current, acute or chronic infection histories. Of the 1535 sampled individuals, 1319 (85.9%) showed a serological evidence of exposure to HBV infection, some through natural infection (22.7%) and others (13.0%) through vaccination; 12% of the exposed were inferred to be currently infected and 91.2% chronically infected. Hepatitis delta virus (HDV) antigen was also detected in 2.7% of the HBsAg positive individuals; and was encountered more (6.7%) in those with acute hepatitis than those with chronic disease. Thus, there are apparently healthy persons with acute and chronic HBV and HDV infection who may serve as source of infection to others. This calls for a government organized Hepatitis Programme to treat cases of acute and chronic hepatitis and roll out strategy for preventing the spread of HBV infections.

show abstract

Section: E M Mbaawuaga Et Alcontrasting

confidence: 45%

“…The higher, though not statistically significant (P > 0.05), HBeAg, acute HBV infection and chronic HBeAg positive males subjects in this study may raise concern since males seems to be more prone to persistent HBV liver diseases, cirrhosis and primary liver cancer [29].…”

Section: E M Mbaawuaga Et Almentioning

confidence: 87%

Hepatitis B Virus (HBV) Serological Patterns in Benue State, Nigeria

Mbaawuaga¹,

Iroegbu²,

Ike³

2014

OJMM

View full text Add to dashboard Cite

show abstract

Pharmacological treatments for acute hepatitis B infection: a network meta-analysis

Gurusamy

Tsochatzis

Thorburn

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Pharmacological interventions for acute hepatitis B infection

Kalafateli

Buzzetti

Thorburn

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Low or very low quality evidence suggests that progression to chronic HBV infection was higher in people receiving lamivudine compared with placebo, no intervention, or entecavir. Low quality evidence suggests that interferon may increase the adverse events after treatment for acute HBV infection. Based on a very low quality evidence, there is currently no evidence of benefit of any intervention in acute HBV infection. There is significant uncertainty in the results and further RCTs are required.

show abstract

Clinical outcome of a patient cohort with acute hepatitis B

Cited by 4 publications

References 27 publications

Hepatitis B Virus (HBV) Serological Patterns in Benue State, Nigeria

Hepatitis B Virus (HBV) Serological Patterns in Benue State, Nigeria

Pharmacological treatments for acute hepatitis B infection: a network meta-analysis

Pharmacological interventions for acute hepatitis B infection

Contact Info

Product

Resources

About